Literature DB >> 16543589

Liver tumor model with implanted rhabdomyosarcoma in rats: MR imaging, microangiography, and histopathologic analysis.

Feng Chen1, Xihe Sun, Frederik De Keyzer, Jie Yu, Ronald Peeters, Walter Coudyzer, Vincent Vandecaveye, Willy Landuyt, Hilde Bosmans, Paul Van Hecke, Guy Marchal, Yicheng Ni.   

Abstract

In compliance with institutional regulations for care and use of laboratory animals, the aim of this study was to establish and characterize a rodent liver tumor model to provide a platform for preclinical assessment of new diagnostic and therapeutic strategies. A rhabdomyosarcoma tumor was implanted in the right and left liver lobes of 20 rats, for a total of 40 tumors. T1- and T2-weighted magnetic resonance (MR) images, diffusion-weighted images, and dynamic susceptibility contrast agent-enhanced perfusion-weighted images were obtained up to 16 days after tumor implantation and were compared with postmortem three-dimensional computed tomographic (CT) images, digital microangiograms, and histopathologic findings. Fifteen tumors were examined with proton ((1)H) MR spectroscopy. All tumors grew, with a mean volume doubling time of 2.2 days +/- 0.9 (standard deviation) and a final size of 591 mm(3)+/- 124. The rhabdomyosarcoma tumor showed hypervascularity at MR imaging, three-dimensional CT, microangiography, and histologic analysis. On dynamic susceptibility contrast-enhanced perfusion-weighted images, the maximum signal intensity decrease differed in time and extent between the tumor and the liver, with a significantly (P < .001) higher relative blood volume, relative blood flow, and permeability value in the tumor than in the liver. With (1)H MR spectroscopy, the rhabdomyosarcoma tumor and the liver featured significant (P < .001) choline and lipid peaks, respectively. Implantation of a rhabdomyosarcoma tumor in the livers of rats is feasible and reproducible, and this animal model seems promising for future testing of new diagnostic and therapeutic strategies. (c) RSNA, 2006.

Entities:  

Mesh:

Year:  2006        PMID: 16543589     DOI: 10.1148/radiol.2392050277

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  18 in total

1.  A high-precision contrast injector for small animal x-ray digital subtraction angiography.

Authors:  Ming de Lin; Lutao Ning; Cristian T Badea; Nilesh N Mistry; Yi Qi; G Allan Johnson
Journal:  IEEE Trans Biomed Eng       Date:  2008-03       Impact factor: 4.538

2.  Development and preliminary testing of a translational model of hepatocellular carcinoma for MR imaging and interventional oncologic investigations.

Authors:  Scott M Thompson; Matthew R Callstrom; Bruce Knudsen; Jill L Anderson; Rickey E Carter; Joseph P Grande; Lewis R Roberts; David A Woodrum
Journal:  J Vasc Interv Radiol       Date:  2012-01-20       Impact factor: 3.464

3.  Diverse responses to vascular disrupting agent combretastatin a4 phosphate: a comparative study in rats with hepatic and subcutaneous tumor allografts using MRI biomarkers, microangiography, and histopathology.

Authors:  Junjie Li; Feng Chen; Yuanbo Feng; Marlein Miranda Cona; Jie Yu; Alfons Verbruggen; Jian Zhang; Raymond Oyen; Yicheng Ni
Journal:  Transl Oncol       Date:  2013-02-01       Impact factor: 4.243

4.  Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumours.

Authors:  Huaijun Wang; Junjie Li; Feng Chen; Frederik De Keyzer; Jie Yu; Yuanbo Feng; Johan Nuyts; Guy Marchal; Yicheng Ni
Journal:  Eur Radiol       Date:  2010-02-25       Impact factor: 5.315

5.  Feng Chen's work on translational and clinical imaging.

Authors:  Feng Chen
Journal:  World J Radiol       Date:  2011-04-28

6.  Quantification of choline concentration following liver cell apoptosis using 1H magnetic resonance spectroscopy.

Authors:  Zhi-Wei Shen; Zhen Cao; Ke-Zeng You; Zhong-Xian Yang; Ye-Yu Xiao; Xiao-Fang Cheng; Yao-Wen Chen; Ren-Hua Wu
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

7.  Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors.

Authors:  Giuseppe La Regina; Ruoli Bai; Whilelmina Maria Rensen; Erica Di Cesare; Antonio Coluccia; Francesco Piscitelli; Valeria Famiglini; Alessia Reggio; Marianna Nalli; Sveva Pelliccia; Eleonora Da Pozzo; Barbara Costa; Ilaria Granata; Amalia Porta; Bruno Maresca; Alessandra Soriani; Maria Luisa Iannitto; Angela Santoni; Junjie Li; Marlein Miranda Cona; Feng Chen; Yicheng Ni; Andrea Brancale; Giulio Dondio; Stefania Vultaggio; Mario Varasi; Ciro Mercurio; Claudia Martini; Ernest Hamel; Patrizia Lavia; Ettore Novellino; Romano Silvestri
Journal:  J Med Chem       Date:  2012-12-27       Impact factor: 7.446

8.  Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation.

Authors:  Marlein Miranda Cona; Yeranddy Aguiar Alpizar; Junjie Li; Matthias Bauwens; Yuanbo Feng; Ziping Sun; Jian Zhang; Feng Chen; Karel Talavera; Peter de Witte; Alfons Verbruggen; Raymond Oyen; Yicheng Ni
Journal:  Pharm Res       Date:  2013-08-09       Impact factor: 4.200

9.  Separate calculation of DW-MRI in assessing therapeutic effect in liver tumors in rats.

Authors:  Feng Chen; Frederik De Keyzer; Yuan-Bo Feng; Marlein Miranda Cona; Jie Yu; Guy Marchal; Raymond Oyen; Yi-Cheng Ni
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

Review 10.  High-field small animal magnetic resonance oncology studies.

Authors:  Louisa Bokacheva; Ellen Ackerstaff; H Carl LeKaye; Kristen Zakian; Jason A Koutcher
Journal:  Phys Med Biol       Date:  2013-12-30       Impact factor: 3.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.